Meaningful benefits: a framework to assess disease-modifying therapies in preclinical and early Alzheimer’s disease

BACKGROUND: The need for preventive therapies that interrupt the progression of Alzheimer’s disease (AD) before the onset of symptoms or when symptoms are emerging is urgent and has spurred the ongoing development of disease-modifying therapies (DMTs) in preclinical and early AD (mild cognitive impa...

Descripción completa

Detalles Bibliográficos
Autores principales: Assunção, Sheila Seleri, Sperling, Reisa A., Ritchie, Craig, Kerwin, Diana R., Aisen, Paul S., Lansdall, Claire, Atri, Alireza, Cummings, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017027/
https://www.ncbi.nlm.nih.gov/pubmed/35440022
http://dx.doi.org/10.1186/s13195-022-00984-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9017027/
https://www.ncbi.nlm.nih.gov/pubmed/35440022
http://dx.doi.org/10.1186/s13195-022-00984-y

Ejemplares similares